NEW YORK (GenomeWeb News) — Enigma Diagnostics said today it has developed a DNA assay for the UK healthcare system to screen for Chlamydia trachomatis, the most common treatable sexually transmitted disease in that country.
Enigma, based in Porton Down, UK, said its assay, reagents, and instrumentation can detect C. trachomatis DNA from urine and or swab samples “in a matter of minutes.” The test is based on Enigma's fully automated diagnostics platform, which uses real-time PCR to detect bacterial target DNA in samples.
Enigma said the Defense Science and Technology Laboratory commissioned the company to create a swift, point-of-care diagnostic for the UK National Chlamydia Screening Program.
Financial terms of the agreement were not released.